| Year | Federal $ expended | Auditor | Opinion | Flags |
|---|---|---|---|---|
| 2025 | $22.9M | Grant Thornton LLP | Unmodified (clean) | Low-risk auditee |
| 2024 | $26.5M | Grant Thornton LLP | Unmodified (clean) | Low-risk auditee |
| 2023 | $25.8M | Grant Thornton LLP | Unmodified (clean) | |
| 2022 | $24.0M | Grant Thornton LLP | Unmodified (clean) |
| Program | Agency | Expended | Major program | Findings |
|---|---|---|---|---|
| Cancer Treatment Research | HHS | $8.3M | Yes | 0 |
| Cancer Treatment Research via The University of Chicago | HHS | $3.0M | Yes | 0 |
| Cancer Treatment Research via RTOG Foundation, Inc. | HHS | $2.3M | Yes | 0 |
| Cancer Control via RTOG Foundation, Inc. | HHS | $1.6M | Yes | 0 |
| Cancer Treatment Research via ECOG ACRIN Medical Research Foundation | HHS | $1.4M | Yes | 0 |
| Cancer Control via ECOG ACRIN Medical Research Foundation | HHS | $1.4M | Yes | 0 |
| Lung BPA Study via Booz Allen Hamilton | HHS | $1.2M | Yes | 0 |
| Cancer Control via NRG Oncology Foundation, Inc. | HHS | $1.2M | Yes | 0 |
| Medical Imaging and Data Resource Center via The University of Chicago | HHS | $692K | Yes | 0 |
| Cancer Control via ECOG ACRIN Medical Research Foundation | HHS | $661K | Yes | 0 |